S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

• I. Dekhtiarenko,
• I. Lelios,
• J. Attig,
• N. Sleiman,
• D. Lazzaro,
• I. Clausen,
• N. Gräfe,
• H.-J. Helms,
• E. Schindler,
• S. Belli,
• T. Fauti,
• J. Eckmann,
• P. Umana,
• W. Jacob,
• M. Schneider,
• C. Hasselbalch Riley,
• M. Hutchings,
• S.-S. Yoon,
• Y Koh,
• S. Manier,
• T. Facon,
• S. J. Harrison,
• J. Er,
• F. Volzone,
• A. Pinto,
• C. Montes,
• E. M. Ocio,
• A. Alfonso-Pierola,
• P. Rodríguez Otero,
• F. Offner,
• A. Guidetti,
• P. Corradini,
• C. Titouan,
• C. Hulin,
• C. Touzeau,
• P. Moreau,
• R. Popat,
• S. Leong,
• R. Mazza,
• C. Carlo-Stella,
• A.-M. E. Bröske

Affiliations

I. Dekhtiarenko

1 Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Zurich

I. Lelios

2 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

J. Attig

2 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

N. Sleiman

2 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

D. Lazzaro

2 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

I. Clausen

2 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

N. Gräfe

3 Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

H.-J. Helms

2 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

E. Schindler

2 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

S. Belli

2 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

T. Fauti

1 Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Zurich

J. Eckmann

3 Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

P. Umana

1 Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Zurich

W. Jacob

3 Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

M. Schneider

2 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

C. Hasselbalch Riley

4 Rigshospitalet, Copenhagen, Denmark

M. Hutchings

4 Rigshospitalet, Copenhagen, Denmark

S.-S. Yoon

5 Seoul National University College of Medicine, Seoul, South Korea

Y Koh

5 Seoul National University College of Medicine, Seoul, South Korea

S. Manier

6 Lille University Hospital, Lille, France

T. Facon

6 Lille University Hospital, Lille, France

S. J. Harrison

7 Peter MacCallum Cancer Center and Royal Melbourne Hospital, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

J. Er

7 Peter MacCallum Cancer Center and Royal Melbourne Hospital, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

F. Volzone

8 Istituto Nazionale dei Tumori, Fondazione Pascale, IRCCS, Napoli, Italy

A. Pinto

8 Istituto Nazionale dei Tumori, Fondazione Pascale, IRCCS, Napoli, Italy

C. Montes

9 Hospital Universitario Marques de Valdecilla (IDIVAL), Universidad de Cantabria, Santander

E. M. Ocio

9 Hospital Universitario Marques de Valdecilla (IDIVAL), Universidad de Cantabria, Santander

A. Alfonso-Pierola

10 Clinica Universidad de Navarra, Navarra, Spain

P. Rodríguez Otero

10 Clinica Universidad de Navarra, Navarra, Spain

F. Offner

11 Universitair Ziekenhuis Gent, Gent, Belgium

A. Guidetti

12 Istituto Nazionale dei Tumori, Milano, Italy

P. Corradini

12 Istituto Nazionale dei Tumori, Milano, Italy

C. Titouan

13 CHU de Bordeaux, Bordeaux

C. Hulin

13 CHU de Bordeaux, Bordeaux

C. Touzeau

14 CHU de Nantes, Nantes, France

P. Moreau

14 CHU de Nantes, Nantes, France

R. Popat

15 University College London Hospitals NHS Foundation Trust, London, United Kingdom

S. Leong

15 University College London Hospitals NHS Foundation Trust, London, United Kingdom

R. Mazza

16 Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milano, Italy

C. Carlo-Stella

16 Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milano, Italy

A.-M. E. Bröske

3 Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany